{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:27:01Z","timestamp":1779895621393,"version":"3.53.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015498","name":"Innov\u00e1ci\u00f3s \u00e9s Technol\u00f3giai Miniszt\u00e9rium","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015498","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012550","name":"Nemzeti Kutat\u00e1si, Fejleszt\u00e9si \u00e9s Innovaci\u00f3s Alap","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012550","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011019","name":"Nemzeti Kutat\u00e1si Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal","doi-asserted-by":"publisher","award":["K139059"],"award-info":[{"award-number":["K139059"]}],"id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clgc.2025.102421","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T23:11:32Z","timestamp":1756768292000},"page":"102421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Lymphovascular Invasion is Predictive for Adjuvant Platinum Therapy Benefit in Urothelial Bladder Cancer"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4919-5901","authenticated-orcid":false,"given":"D\u00e1niel","family":"Juh\u00e1sz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Csizmarik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7733-0831","authenticated-orcid":false,"given":"Melinda","family":"V\u00e1radi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e1niel","family":"Bacs\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6901-9701","authenticated-orcid":false,"given":"Andr\u00e1s","family":"Kubik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikl\u00f3s","family":"Sz\u0171cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eszter","family":"Sz\u00e9kely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7213-9417","authenticated-orcid":false,"given":"Mulham","family":"Al-Nader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Krafft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Nyir\u00e1dy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6321-0799","authenticated-orcid":false,"given":"Tibor","family":"Szarvas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clgc.2025.102421_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.clgc.2025.102421_bib0002","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 Guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.clgc.2025.102421_bib0003","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","article-title":"Neoadjuvant chemotherapy for muscle-invasive bladder cancer: A systematic review and two-step meta-analysis","volume":"21","author":"Yin","year":"2016","journal-title":"Oncologist"},{"issue":"16","key":"10.1016\/j.clgc.2025.102421_bib0004","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","volume":"29","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clgc.2025.102421_bib0005","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"#cr-split#-10.1016\/j.clgc.2025.102421_bib0006.1","doi-asserted-by":"crossref","unstructured":"Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005 Aug;48(2):202-5","DOI":"10.1016\/j.eururo.2005.04.006"},{"key":"#cr-split#-10.1016\/j.clgc.2025.102421_bib0006.2","doi-asserted-by":"crossref","unstructured":"discussion 205-6. doi:10.1016\/j.eururo.2005.04.006. Epub 2005 Apr 21. PMID: 15939524.","DOI":"10.1016\/j.eururo.2005.04.006"},{"key":"10.1016\/j.clgc.2025.102421_bib0007","first-page":"213","article-title":"EORTC Group Study 30851: a phase II study of neoadjuvant chemotherapy in patients with invasive bladder cancer","volume":"353","author":"Splinter","year":"1990","journal-title":"Prog Clin Biol Res"},{"issue":"19","key":"10.1016\/j.clgc.2025.102421_bib0008","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative Durvalumab with Neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102421_bib0009","series-title":"2023 ASCO Genitourinary Cancers Symposium; San Francisco, California, USA: Journal of Clinical Oncology","article-title":"Perioperative enfortumab vedotin (EV) plus pembrolizumab (pembro) versus chemotherapy in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): phase 3 KEYNOTE-B15\/EV-304","author":"Christopher","year":"2023"},{"issue":"1","key":"10.1016\/j.clgc.2025.102421_bib0010","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.eururo.2021.09.028","article-title":"Advanced bladder cancer meta-analysis collaborators G. Adjuvant chemotherapy for muscle-invasive bladder cancer: A systematic review and meta-analysis of individual participant data from randomised controlled trials","volume":"81","year":"2022","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.clgc.2025.102421_bib0011","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2217\/fon-2022-0868","article-title":"IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery","volume":"19","author":"Jackson-Spence","year":"2023","journal-title":"Future Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102421_bib0012","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa2401726","article-title":"Adjuvant Pembrolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"392","author":"Apolo","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clgc.2025.102421_bib0013","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.clgc.2023.10.014","article-title":"Patients with muscle-invasive bladder cancer with lymphovascular invasion in transurethral resection specimen benefits most from platinum-based neoadjuvant chemotherapy","volume":"22","author":"Wang","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2025.102421_bib0014","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3389\/fonc.2020.00487","article-title":"The prognostic value of lymphovascular invasion in patients with upper tract urinary carcinoma after surgery: an updated systematic review and meta-analysis","volume":"10","author":"Zhang","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102421_bib0015","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3390\/cancers16010123","article-title":"Lymphovascular invasion at the time of radical prostatectomy adversely impacts oncological outcomes","volume":"16","author":"Sathianathen","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.clgc.2025.102421_bib0016","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/s12957-023-03273-6","article-title":"Lymphovascular invasion is a significant risk factor for non-sentinel nodal metastasis in breast cancer patients with sentinel lymph node (SLN)-positive breast cancer: a cross-sectional study","volume":"21","author":"Wei","year":"2023","journal-title":"World J Surg Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102421_bib0017","doi-asserted-by":"crossref","DOI":"10.1093\/dote\/doy083","article-title":"Lymphovascular invasion as a poor prognostic indicator in thoracic esophageal carcinoma: a systematic review and meta-analysis","volume":"32","author":"Wang","year":"2019","journal-title":"Dis Esophagus"},{"issue":"6","key":"10.1016\/j.clgc.2025.102421_bib0018","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1200\/JCO.2002.20.6.1527","article-title":"Simplified staging for hepatocellular carcinoma","volume":"20","author":"Vauthey","year":"2002","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102421_bib0019","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12885-022-10416-7","article-title":"Lymphovascular invasion represents a superior prognostic and predictive pathological factor of the duration of adjuvant chemotherapy for stage III colon cancer patients","volume":"23","author":"Zhang","year":"2023","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2025.102421_bib0020","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1186\/s12885-019-5924-6","article-title":"Clinicopathological factors in bladder cancer for cancer-specific survival outcomes following radical cystectomy: a systematic review and meta-analysis","volume":"19","author":"Zhang","year":"2019","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2025.102421_bib0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089259","article-title":"Prognostic significance of lymphovascular invasion in radical cystectomy on patients with bladder cancer: a systematic review and meta-analysis","volume":"9","author":"Kim","year":"2014","journal-title":"PLoS One"},{"issue":"17","key":"10.1016\/j.clgc.2025.102421_bib0022","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1158\/1078-0432.CCR-10-0457","article-title":"The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder","volume":"16","author":"Svatek","year":"2010","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T21:09:39Z","timestamp":1770671379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325001211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1558767325001211"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102421","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lymphovascular Invasion is Predictive for Adjuvant Platinum Therapy Benefit in Urothelial Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102421","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102421"}}